|Ipilimumab plus dacarbazine for previously untreated metastatic melanoma|
C Robert, L Thomas, I Bondarenko, S O'Day, J Weber, C Garbe, C Lebbe, ...
New England Journal of Medicine 364 (26), 2517-2526, 2011
|Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer|
C Bokemeyer, I Bondarenko, A Makhson, JT Hartmann, J Aparicio, ...
Journal of clinical oncology 27 (5), 663-671, 2009
|The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative …|
RS Finn, JP Crown, I Lang, K Boer, IM Bondarenko, SO Kulyk, J Ettl, ...
The lancet oncology 16 (1), 25-35, 2015
|Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma|
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F de Braud, J Larkin, ...
New England Journal of Medicine 371 (20), 1877-1888, 2014
|Risk of natalizumab-associated progressive multifocal leukoencephalopathy|
G Bloomgren, S Richman, C Hotermans, M Subramanyam, S Goelz, ...
New England Journal of Medicine 366 (20), 1870-1880, 2012
|Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non–small-cell lung cancer: results from a randomized, double-blind …|
TJ Lynch, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, ...
Journal of clinical oncology 30 (17), 2046-2054, 2012
|Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial|
GV Long, D Stroyakovskiy, H Gogas, E Levchenko, F De Braud, J Larkin, ...
The Lancet 386 (9992), 444-451, 2015
|RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor …|
NJ Robert, V Diéras, J Glaspy, AM Brufsky, I Bondarenko, ON Lipatov, ...
Journal of clinical oncology 29 (10), 1252-1260, 2011
|Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous …|
M Cristofanilli, NC Turner, I Bondarenko, J Ro, SA Im, N Masuda, ...
The Lancet Oncology 17 (4), 425-439, 2016
|Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study|
C Bokemeyer, I Bondarenko, JT Hartmann, F De Braud, G Schuch, ...
Annals of oncology 22 (7), 1535-1546, 2011
|Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised …|
M Reck, R Kaiser, A Mellemgaard, JY Douillard, S Orlov, M Krzakowski, ...
The lancet oncology 15 (2), 143-155, 2014
|Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer|
A Di Leo, G Jerusalem, L Petruzelka, R Torres, IN Bondarenko, ...
J Clin Oncol 28 (30), 4594-4600, 2010
|Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung …|
MA Socinski, I Bondarenko, NA Karaseva, AM Makhson, I Vynnychenko, ...
J Clin Oncol 30 (17), 2055-2062, 2012
|Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma|
BI Rini, ER Plimack, V Stus, R Gafanov, R Hawkins, D Nosov, F Pouliot, ...
New England Journal of Medicine 380 (12), 1116-1127, 2019
|Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind …|
M Reck, I Bondarenko, A Luft, P Serwatowski, F Barlesi, R Chacko, ...
Annals of Oncology 24 (1), 75-83, 2013
|Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study|
SJ O'day, M Maio, V Chiarion-Sileni, TF Gajewski, H Pehamberger, ...
Annals of Oncology 21 (8), 1712-1717, 2010
|Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label …|
TSK Mok, YL Wu, I Kudaba, DM Kowalski, BC Cho, HZ Turna, G Castro Jr, ...
The Lancet 393 (10183), 1819-1830, 2019
|Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial|
RJ Motzer, D Nosov, T Eisen, I Bondarenko, V Lesovoy, O Lipatov, ...
Journal of clinical oncology 31 (30), 3791, 2013
|Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial|
M Maio, JJ Grob, S Aamdal, I Bondarenko, C Robert, L Thomas, C Garbe, ...
Journal of clinical oncology 33 (10), 1191, 2015
|KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience|
C Bokemeyer, I Bondarenko, JT Hartmann, FG De Braud, C Volovat, ...
Journal of Clinical Oncology 26 (15_suppl), 4000-4000, 2008